IPO Year: 2021
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/13/2024 | Equal-Weight → Underweight | Morgan Stanley | |
| 3/15/2024 | $20.00 → $15.00 | Buy | Needham |
| 3/15/2024 | Outperform → Market Perform | TD Cowen | |
| 3/15/2024 | $16.00 → $3.00 | Buy → Hold | Jefferies |
| 12/1/2023 | $20.00 | Buy | Needham |
| 6/26/2023 | $25.00 | Outperform | Oppenheimer |
| 4/19/2023 | $5.00 → $14.00 | Underweight → Equal-Weight | Morgan Stanley |
| 4/19/2023 | $10.00 → $20.00 | Neutral → Buy | Mizuho |
| 3/30/2023 | $10.00 | Neutral | Mizuho |
| 2/3/2023 | $12.00 → $5.00 | Equal-Weight → Underweight | Morgan Stanley |
8-K - Immuneering Corp (0001790340) (Filer)
8-K - Immuneering Corp (0001790340) (Filer)
10-Q - Immuneering Corp (0001790340) (Filer)
8-K - Immuneering Corp (0001790340) (Filer)
8-K/A - Immuneering Corp (0001790340) (Filer)
8-K - Immuneering Corp (0001790340) (Filer)
10-Q - Immuneering Corp (0001790340) (Filer)
8-K - Immuneering Corp (0001790340) (Filer)
8-K - Immuneering Corp (0001790340) (Filer)
8-K - Immuneering Corp (0001790340) (Filer)
SC 13G/A - Immuneering Corp (0001790340) (Subject)
SC 13G/A - Immuneering Corp (0001790340) (Subject)
SC 13G/A - Immuneering Corp (0001790340) (Subject)
SC 13G/A - Immuneering Corp (0001790340) (Subject)
SC 13G/A - Immuneering Corp (0001790340) (Subject)
SC 13G/A - Immuneering Corp (0001790340) (Subject)
SC 13G/A - Immuneering Corp (0001790340) (Subject)
SC 13G/A - Immuneering Corp (0001790340) (Subject)
SC 13G - Immuneering Corp (0001790340) (Subject)
SC 13G/A - Immuneering Corp (0001790340) (Subject)
Morgan Stanley downgraded Immuneering Corporation from Equal-Weight to Underweight
Needham reiterated coverage of Immuneering Corporation with a rating of Buy and set a new price target of $15.00 from $20.00 previously
TD Cowen downgraded Immuneering Corporation from Outperform to Market Perform
Jefferies downgraded Immuneering Corporation from Buy to Hold and set a new price target of $3.00 from $16.00 previously
Needham initiated coverage of ImaRx Therapeutics with a rating of Buy and set a new price target of $20.00
Oppenheimer resumed coverage of ImaRx Therapeutics with a rating of Outperform and set a new price target of $25.00
Morgan Stanley upgraded ImaRx Therapeutics from Underweight to Equal-Weight and set a new price target of $14.00 from $5.00 previously
Mizuho upgraded ImaRx Therapeutics from Neutral to Buy and set a new price target of $20.00 from $10.00 previously
Mizuho initiated coverage of ImaRx Therapeutics with a rating of Neutral and set a new price target of $10.00
Morgan Stanley downgraded ImaRx Therapeutics from Equal-Weight to Underweight and set a new price target of $5.00 from $12.00 previously
4 - Immuneering Corp (0001790340) (Issuer)
4 - Immuneering Corp (0001790340) (Issuer)
4 - Immuneering Corp (0001790340) (Issuer)
4 - Immuneering Corp (0001790340) (Issuer)
4 - Immuneering Corp (0001790340) (Issuer)
4 - Immuneering Corp (0001790340) (Issuer)
4 - Immuneering Corp (0001790340) (Issuer)
4 - Immuneering Corp (0001790340) (Issuer)
4 - Immuneering Corp (0001790340) (Issuer)
- Reported Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors - - First Patient Dosed in Phase 2a Portion of Phase 1/2a Clinical Trial of IMM-1-104; Initial Data from Multiple IMM-1-104 Phase 2a Arms Expected in 2024 - - Presented Preclinical Data at AACR Demonstrating that Combining IMM-1-104 with Chemotherapies Used in The Treatment of First-line Pancreatic Cancer Yielded Deeper and More Durable Tumor Growth Inhibition Than Either Treatment Alone - - First Patient Dosed in Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations; Initial PK, PD and safety data expected in 2024 - CAMBRIDGE
CAMBRIDGE, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced the appointment of Thomas J. Schall, Ph.D., former Chairman, CEO and Founder of ChemoCentryx before its acquisition by Amgen, to its Board of Directors. "On behalf of the entire Immuneering team, we are honored to welcome Dr. Schall to our Board," said Ben Zeskind, Chief Executive Officer, Immuneering Corporation. "Tom's extensive experience developing new medicines, including 25 years guiding drug discovery, development and commercialization
- Positive Initial Phase 1 Pharmacokinetic, Pharmacodynamic and Safety Data for IMM-1-104 Universal-RAS Program presented at American Association for Cancer Research (AACR) annual meeting - -First demonstration of novel deep cyclic inhibition mechanism in humans, with IMM-1-104 achieving significant levels of PK Cmax and a half-life of approximately two hours as predicted - - Study timeline for IMM-1-104 accelerated: recommended Phase 2 dose (RP2D) now expected in early 2024- - Pharmacodynamic data support potential to evaluate preliminary efficacy sooner than expected - - Completed $30 million underwritten offering; Projected cash runway extended into 2025 - CAMBRIDGE, Mass., May
CAMBRIDGE, Mass., March 28, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, announced today that it has appointed Harold E. Brakewood ("E.B.") as its Chief Business Officer. Mr. Brakewood, who has more than 25 years of experience as a senior executive in the biotechnology and pharmaceutical industry, will be responsible for corporate and business development, new product planning, and commercial strategy. "We are excited to have E.B. join Immuneering's senior leadership team as we continue to advance our oncology pipeli
Recruiting has Commenced for Phase 1/2a Clinical Trial of IMM-1-104 in Advanced Solid Tumors with RAS Mutations (NCT05585320), with the First Patient Expected to be Dosed this Quarter Shares Promising Preclinical Data on Second Program IMM-6-415 at the 37th Annual Meeting of SITC, Demonstrating Preclinical Single Agent Activity in RAF and RAS Mutant Tumors and Enhancement of PD1 and CTLA4 Checkpoint Blockade Cash, Cash Equivalents and Marketable Securities of $117.2M is Expected to Provide Cash Runway into Q3 2024 CAMBRIDGE, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a biopharmaceutical company that aims to create medicines for all patients with
CAMBRIDGE, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a biopharmaceutical company that aims to create medicines for all patients with solid tumors driven by RAS mutations and other MAPK pathway activation events, today announced the appointment of Leah R. Neufeld to the newly created position of Chief People Officer, effective immediately. "Our world-class team of Immuneers enables us to accomplish great things, and in Leah we now have a Chief People Officer worthy of our people," stated Ben Zeskind, Ph.D., Co-Founder and Chief Executive Officer of Immuneering. "Leah is a seasoned human resources leader with decades of experience in the life scie
BOSTON, Jan. 19, 2022 (GLOBE NEWSWIRE) -- PepGen, Inc., a company advancing next-generation oligonucleotide therapies for neuromuscular and neurologic diseases, today announced that it has appointed Laurie Keating as Chair of the company's Board of Directors. "We are very pleased that Laurie has agreed to join as Chair of our Board of Directors – she is a seasoned executive and Board member who has been a key member of the executive teams of two Boston biotechs that have transitioned from preclinical to successful commercial companies. We look forward to her strategic contributions and guidance as we continue to grow and build PepGen into a leading oligonucleotide therapies company focu
CAMBRIDGE, Mass., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates that are designed to uniquely disrupt cellular signaling dynamics, today announced the appointment of Diana F. Hausman, M.D., Chief Medical Officer of Lengo Therapeutics (a wholly-owned subsidiary of Blueprint Medicines Corporation), to its Board of Directors. This appointment brings Immuneering's Board to six members. "Diana has dedicated her career to creating new and better possibilities for cancer patients, as a Board certified oncologist with more than 20 years of clinical drug development
CAMBRIDGE, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates that are designed to uniquely disrupt cellular signaling dynamics, today announced the appointment of Rimma Steinhertz, Ph.D., PMP to the newly created position of Vice President, Project and Alliance Management, effective immediately. In this role, Dr. Steinhertz will focus on working with Immuneering's leadership team as it advances IMM-1-104 as a monotherapy into clinical trials in 2022 and working with potential future partners to advance combination approaches with IMM-1-104 in select patient
4 - Immuneering Corp (0001790340) (Issuer)
4 - Immuneering Corp (0001790340) (Issuer)
4 - Immuneering Corp (0001790340) (Issuer)
4 - Immuneering Corp (0001790340) (Issuer)
4 - Immuneering Corp (0001790340) (Issuer)
4 - Immuneering Corp (0001790340) (Issuer)
4 - Immuneering Corp (0001790340) (Issuer)
4 - Immuneering Corp (0001790340) (Issuer)
4 - Immuneering Corp (0001790340) (Issuer)
4 - Immuneering Corp (0001790340) (Issuer)
- Updated data for IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic cancer patients show favorable overall response rate (ORR = 43%) and disease control rate (DCR = 86%); planning for pivotal trial underway - - Favorable initial data for IMM-1-104 in combination with modified FOLFIRINOX (mFFX) in first-line pancreatic cancer patients show target lesion shrinkage in all evaluable patients, including a 100% reduction (PR) - - Encouraging initial data for IMM-1-104 monotherapy in second-line pancreatic cancer, including a 67% reduction (PR), demonstrate activity and support development in first-line combinations; over 75 patients enrolled acros
- In Phase 2a arm investigating IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel, complete or partial responses have been observed in the first two patients (2/5) to date, for an initial response rate of 40% and an initial disease control rate of 80%, with all five patients continuing on treatment - - Initial data are at 240 mg QD (safety lead-in dose) of IMM-1-104; additional patients have now been dosed at 320 mg QD in this arm; IMM-1-104 has been well-tolerated to date in combination with gemcitabine/nab-paclitaxel - - Initial data are consistent with preclinical data presented at AACR, which demonstrated that IMM-1-104 combined with chemotherapy induced deeper res
- IMM-1-104 has been well-tolerated, demonstrating the potential for a differentiated safety profile - - 100% suppression of acquired RAS alterations was observed in evaluable patients profiled for ctDNA and treated with IMM-1-104, supporting goal of Universal-RAS activity - - Target lesion regression observed in over half of patients treated with IMM-1-104 at 320mg or 240mg QD, with best individual lesion regression of -35.7% and best RECIST sum of longest diameters (SLD) of -18.9%, both at 320mg - - Candidate RP2D of 320 mg QD supported by tolerability, PK/PD, ctDNA results & initial anti-tumor activity - - Phase 2a portion of the study underway with three monotherapy and two combin
Data presented at AACR Annual Meeting support IMM-1-104's potential to address a broad population of patients with RAS mutant tumorsIMM-1-104 well tolerated with no dose limiting toxicities (DLTs) or serious adverse events (SAEs) observed First demonstration of novel deep cyclic inhibition mechanism in humans, with IMM-1-104 achieving significant levels of PK Cmax and a half-life of approximately two hours as predictedPharmacodynamic data support potential to evaluate preliminary efficacy sooner than expected Study timeline accelerated: recommended Phase 2 dose (RP2D) now expected in early 2024Investor call to be held today at 9.00 a.m. ET CAMBRIDGE, Mass., April 18, 2023 (GLOBE NEWSWIR
CAMBRIDGE, Mass., April 05, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, today announced that it will hold a virtual Investor Event concurrent with a data presentation on its universal-RAS program IMM-1-104 at the American Association for Cancer Research Annual Meeting 2023. The virtual Investor Event will be held at 9:00 a.m. ET on April 18, 2023. To access the Investor Event by phone, please use this registration link, and you will be provided with dial in details. To avoid delays, we encourage participants to di
First patient dosed in Phase 1/2a clinical trial of IMM-1-104 in advanced solid tumors with any RAS mutation Provides debut guidance for IMM-1-104 program: initial Phase 1 PK and safety data expected in mid-2023, initial Phase 1 PD modeling and additional PK and safety data expected in 2H 2023, recommended phase 2 dose and additional safety data expected in mid-2024 Continued progress in oncology pipeline - on track to file IND for IMM-6-415 in Q4 2023 Cash runway extended into Q4 2024; sharpened focus on oncology pipeline and suspension of discovery-stage neuroscience programs Conference call and webcast today at 4:30 p.m. ET. CAMBRIDGE, Mass., March 06, 2023 (GLOBE NEWSWIRE) -- Im
CAMBRIDGE, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, today announced that it plans to release financial results for the fourth quarter and full year ended December 31, 2022 on Monday, March 6 after the close of trading. Immuneering's management team will host a conference call and webcast beginning at 4:30 p.m. ET. To access the call by phone, please use this registration link, and you will be provided with dial in details. To avoid delays, we encourage participants to dial into the conference call fif
- Two new partial responses (PRs) reported in Phase 2a arm studying IMM-1-104 in combination with modified FOLFIRINOX (mFFX) in first-line pancreatic cancer - - Overall Response Rate (ORR) of 50%; historic benchmark of 32% for FOLFIRINOX alone - - Nearly $14M in net proceeds raised in January 2025 through utilization of Company's ATM - CAMBRIDGE, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients, today announced a positive update from its Phase 2a arm studying IMM-1-104 in combination with modified FOLFIRINOX (mFFX) in fir
- Updated data for IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic cancer patients show favorable overall response rate (ORR = 43%) and disease control rate (DCR = 86%); planning for pivotal trial underway - - Favorable initial data for IMM-1-104 in combination with modified FOLFIRINOX (mFFX) in first-line pancreatic cancer patients show target lesion shrinkage in all evaluable patients, including a 100% reduction (PR) - - Encouraging initial data for IMM-1-104 monotherapy in second-line pancreatic cancer, including a 67% reduction (PR), demonstrate activity and support development in first-line combinations; over 75 patients enrolled acros
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Dec. 23, 2024 /PRNewswire/ -- USA News Group News Commentary – Recent advancements in cancer treatment continue to underscore the transformative potential of innovative therapies to improve patient outcomes. A stage 4 breast cancer patient in the United States reportedly achieved complete remission within six weeks through a novel immunotherapy approach, as highlighted by the New York Post. Meanwhile, in Europe, a Scottish woman became the first recipient of a personalized mRNA cancer vaccine, training her immune system to target cancer cells and marking a significant step toward more precise, less toxic treatments. These breakthroug
- Establishment reflects the clinical progress of IMM-1-104 and its promise in pancreatic cancer - - Follows recent Orphan Drug designation in pancreatic cancer and Fast Track designations in first- and second-line pancreatic cancer for IMM-1-104 - CAMBRIDGE, Mass., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced the formation of its Pancreatic Cancer Advisory Board. The advisory board, which comprises world-renowned oncology clinical researchers, will provide strategic medical and clinical guidance to the co
- The company will provide additional data from IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic cancer - - The company will also provide initial data from IMM-1-104 in combination with modified FOLFIRINOX (mFFX) in first-line pancreatic cancer, as well as IMM-1-104 monotherapy in second-line pancreatic cancer - CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that it will hold a virtual Investor Event in early January 2025 to discuss data from
- IMM-1-104 has the potential to benefit melanoma patients who have progressed on or are intolerant to immune checkpoint inhibitors - - IMM-1-104 was observed to be uniquely well tolerated in Phase 1 data shared at ESMO 2024, relative to MEK inhibitors currently used to treat melanoma - - Melanoma patients actively enrolling in one of five arms in the company's ongoing Phase 2a clinical study of IMM-1-104 - CAMBRIDGE, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that the U.S. Food and Drug Administ
CAMBRIDGE, Mass., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that management will present at the Piper Sandler 36th Annual Healthcare Conference, which is taking place at the Lotte New York Palace in New York City from December 3-5, 2024, to discuss the company's pipeline, platform, and business strategy. Participating will be Ben Zeskind, Chief Executive Officer, Harold "E.B." Brakewood, Chief Business Officer and Mallory Morales, CPA, Chief Accounting Officer, Treasurer. Format: Fireside Chat and 1x1
- Announced Positive Initial Data, Including Complete and Partial Responses, with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients - - Granted FDA Orphan Drug Designation for IMM-1-104 in the Treatment of Pancreatic Cancer and Fast Track Designation in First-line Pancreatic Cancer - - Initial Data From At Least One Additional Arm of the Phase 2a Portion of the IMM-1-104 Phase 1/2a Trial Expected by Year End - - Cash Runway into Fourth Quarter 2025 - CAMBRIDGE, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad popul
- Immuneering recently announced positive initial Phase 2a data, including complete and partial responses, with IMM-1-104 in combination with chemotherapy in first-line pancreatic cancer patients - -Initial data from at least one additional arm of the Phase 2a portion of the Company's Phase 1/2a trial is expected by year-end - CAMBRIDGE, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to IMM-1-104 in the treatment of p
- In Phase 2a arm investigating IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel, complete or partial responses have been observed in the first two patients (2/5) to date, for an initial response rate of 40% and an initial disease control rate of 80%, with all five patients continuing on treatment - - Initial data are at 240 mg QD (safety lead-in dose) of IMM-1-104; additional patients have now been dosed at 320 mg QD in this arm; IMM-1-104 has been well-tolerated to date in combination with gemcitabine/nab-paclitaxel - - Initial data are consistent with preclinical data presented at AACR, which demonstrated that IMM-1-104 combined with chemotherapy induced deeper res